<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02661438</url>
  </required_header>
  <id_info>
    <org_study_id>18253</org_study_id>
    <nct_id>NCT02661438</nct_id>
  </id_info>
  <brief_title>Summative Usability Study of Ciprofloxacin Dry Powder for Inhalation Using Placebo</brief_title>
  <official_title>Multicenter Summative Usability Study of Ciprofloxacin Dry Powder for Inhalation in Subjects With Non-Cystic Fibrosis Bronchiectasis (NCFB) or Chronic Obstructive Pulmonary Disease (COPD) Using Matching Placebo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The rationale of this study is to conduct a summative (i.e., validation) usability test of
      Ciprofloxacin Dry Powder for Inhalation (DPI) and the associated Instructions for Use.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The user performed the inhalation task based on the given instructions properly (Yes/No).</measure>
    <time_frame>1 Day</time_frame>
    <description>The performance was assessed by a test administrator.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The user performed the inhalation task safely (Yes/No).</measure>
    <time_frame>1 Day</time_frame>
    <description>The user safety was assessed by a test administrator.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>DPI (Dry powder for inhalation) device malfunction (Yes/No).</measure>
    <time_frame>1 Day</time_frame>
    <description>The function was assessed by a test administrator.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Subject's subjective feedback (paraphrased) on use-safety and usability</measure>
    <time_frame>1 Day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inhalation time</measure>
    <time_frame>1 Day</time_frame>
    <description>Inhalation time is assessed with a stop watch.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>User friendliness</measure>
    <time_frame>1 Day</time_frame>
    <description>User friendliness is assessd by a questionnaire.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Bronchiectasis</condition>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>Placebo to Ciprofloxacin DPI</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Placebo to Ciprofloxacin DPI, 3 doses during test session, 1 additional dose for patients during device training</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to Ciprofloxacin DPI (BAYQ3939)</intervention_name>
    <description>Placebo to Ciprofloxacin DPI, 3 doses during test session, 1 additional dose for patients during device training</description>
    <arm_group_label>Placebo to Ciprofloxacin DPI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Subjects (male and female) with non-cystic fibrosis bronchiectasis (NCFB) or chronic
             obstructive pulmonary disease (COPD)

          -  Subjects must be aged â‰¥40

          -  Subject must be able to independently manage and administer their NCFB/COPD
             medications

        Exclusion Criteria:

          -  Subjects with recent exacerbation

          -  Subjects with recent significant hemoptysis in the four weeks before screening (and/or
             during the screening period)

          -  Subjects allergic to quinine

          -  Known chronic bronchial asthma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Vero Beach</city>
        <state>Florida</state>
        <zip>32960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jamaica</city>
        <state>New York</state>
        <zip>11435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 30, 2015</study_first_submitted>
  <study_first_submitted_qc>January 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2016</study_first_posted>
  <last_update_submitted>April 6, 2016</last_update_submitted>
  <last_update_submitted_qc>April 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Usability Test</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
    <mesh_term>Bronchiectasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ciprofloxacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

